⌕
MoonLake Immunotherapeutics · MLTX · Nasdaq
Tenet 51 · Mixed
Compare
$11.73−6.16%At closeTenet 51 · Mixed
$11.73−0.77 (−6.16%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

MoonLake Immunotherapeutics (MLTX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+335.4%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼90.0%
−230.3
FY21→FY25CAGR —
Free cash flow ($M)▼67.4%
−196.0
no value for 1 of 5 yearsCAGR —
Diluted EPS▼86.8%
−3.53
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+335.4%

14.8mn → 64.5mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$35.0K

−93.3% YoY in FY25.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−202.9R&D−42.0SG&A−244.8Op income14.5Tax & other−230.3Net income

Margin trend · direction beats level
108530%sector median net margin ~4%FY21FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.755, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.00.00.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.00.00.0——
Research & development
229,613.0202,862.0112,771.031,802.042,049.0—▲79.9%+69.0%
Selling, general & admin
47,140.041,972.030,320.022,321.023,012.54,570.3▲38.4%+74.1%
Total operating expenses
276,753.0244,834.0143,091.054,123.065,061.44,570.3▲71.1%+170.5%
Operating incomefeeds ROC rank
−276,753.0−244,834.0−143,091.0−54,123.0−65,061.4−4,570.3▼71.1%—
Other income, net
4,270.015,124.022,129.010,138.0591.727.7——
Pretax income
−272,483.0−229,710.0−120,962.0−43,985.0−64,469.7−4,542.7▼89.9%—
Income tax
1,591.0611.0282.094.036.4—▲116.7%+156.1%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−274,074.0−230,321.0−121,244.0−44,079.0−64,506.1−4,542.7▼90.0%—
Per share
Diluted EPSbuyback-sensitive
−3.65−3.53−1.89−0.73−1.70−0.31▼86.8%—
Diluted shares (mn)
85.3864.4662.8749.1229.3614.80▲2.5%+44.5%
Margins
† TTM = trailing four quarters through 2026-09-30.
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.